版权说明：本文档由用户提供并上传，收益归属内容提供方，若内容存在侵权，请进行举报或认领
文档简介
甲状腺髓样癌的分子分型及治疗
解放军第一一七医院
戚晓平甲状腺髓样癌的分子分型及治疗解放军第一一概况Histologicsubtypesof
thyroidcancer
①Papillary:approximately80%ofallthyroidmalignancies;
②FollicularandHürthle:approximately11%;
③Medullary:lessthan5%-8%;
④Anaplastic:lessthan2%.
概况HistologicsubtypesofthyroIntroductionMedullarythyroidcancer(MTC)①SporadicMTC:
approximately75%;>50%somatic
RET
mutations(p.M918T)-predictapoorprognosis
②HereditaryMTC:
approximately25%;
98%Germline
RET
mutations,MEN2A(~95%)andMEN2B(~5%)
Arisesfromtheneuralcrest-derived,calcitonin-secreting,parafollicularCcellsofthethyroidgland
IntroductionMedullarythyroidIntroduction①SporadicMTC:
asolitaryandunilateralorapalpablecervicallymphnode
②HereditaryMTC:multicentricandbilateraltheuppertomiddlepartsofthethyroidlobes
Introduction①SporadicMTC:aIntroductionInvolvementofcervicallymphnodesisanearlyandcommonmanifestationintheclinicalcourseofthedisease,with35%to50%ormore,another10%to15%mayhavedistantmetastasesatthetimeofinitialpresentation;
DistantmetastaticspreadofMTCfrequentlyinvolvesthemediastinalnodes,lung,liver(>90%),andbones.
IntroductionInvolvementofcep.C611YMEN2Ap.C611YMolecularAberrations
(overexpression)
①RET
mutations②VEGFR-2③MET④EGFR⑤
FGFR⑥
RAS
(sMTC---56%KRAS+;12%HRAS)(MutationsinRASappeartobemutuallyexclusiveofRETabnormalities)
SomaticRETmutationsMolecularAberrations(overexpMolecularpathways①PI3K/Akt/mTOR②MAPK③JNK④RAS/ERKPlaycriticalrolesinregulatingcellproliferation,differentiation,motility,apoptosis,andsurvival
Molecularpathways①PI3K/Akt/DiagnosisandMonitoring①FNA,USandCT,MRIorECT(Ct>500pg/mL);
②DNAanalysisfortheRETgermlinemutation
ATA-2015,ETA-2013,NCCN-2017Guidelinesrecommend
③
TheMTCspecimenispositivelystainedforCt,chromograninA,andCEAorCongoRed.
DiagnosisandMonitoring①FNA,DiagnosisandMonitoring
④Serum-basedbiomarkers:
calcitoninandCEA(>50%)Preoperative:ⅰCEA(↑),Ct(-)--poorlydifferentiatedtumors,Rare;
ⅱCt>100pg/mL--predictive–MTC;
ⅲCt>150pg/mL,CEA>30ng/L--regionalspread;
ⅳCt>3000pg/mL,CEA>100ng/L--distantspread.PredictorsofMTCprogress,includingrecurrenceandsurvival
DiagnosisandMonitoring④SeruDiagnosisandMonitoring④Serum-basedbiomarkers:
calcitoninandCEAPostoperative:ⅰCt(↑)--thefirstsignoftumorrecurrence;ⅱCt(-)andsCt(-)--10-yearsurvivalrates(SR)of100%;yearlyCtmeasurements;
ⅲCtdoublingtimes(DT)>1yr(2yr)--5-and10-yrSR
of98%and95%;CEADT>1yr--5-and10-yrSRof100%；
ⅳCtDT<1yr(6mon)--5-and10-yrSR
of36%and18%（25%and8%）;CEA<1year--5-and10-yrSRof43%and21%.
PredictorsofMTCprogress,includingrecurrenceandsurvival
DiagnosisandMonitoring④SerumDiagnosisandMonitoring●10-yrSRforpatientswithstagesI,II,III,andIVMTCare100%,93%,71%,and21%,respectively;●SRforpatientswithdistantmetastasesMTCis51%at1yr,26%at5yr,and10%at10yr,respectively.
●DiagnosisandMonitoring●10-yrATA-2015GuidelinesrecommendedATA-2015Guidelinesrecommende甲状腺髓样癌的分子分型及治疗-课件MEN2B-denovo
RET
p.M918TMEN2B-denovoRETp.M918TMEN2B-denovo
RET
p.M918TMEN2B-denovoRETp.M918TMEN2A-CLA,RETp.C634R/FMEN2A-CLA,RETp.C634R/F甲状腺髓样癌的分子分型及治疗-课件SurgicalManagementofMTC
①Theminimumextentofsurgeryisatotalthyroidectomy(TT)withbilateralcentralneckdissection(BiⅥ)
(TT+BiⅥLND);②TTwithipsilaterallateralcompartmentneckdissection;
(Unilaterallateral
LN+,MTCsize>1cm)
(TT+BiⅥ+UniLND)③TTwithbilaterallateralcompartmentneckdissection.(BilateraltumorsorextensiveLN+onthecontralateralside)
(TT+BiⅥ+BiLND)SurgicalManagementofMTC①Th甲状腺髓样癌的分子分型及治疗-课件SurgicalManagementofMTC***CurrentrecommendationsforthetimingofprophylacticthyroidectomydependsontheriskleveloftheRETmutationinhereditaryMTC(MEN2).
SurgicalManagementofMTCATA-2015GuidelinesrecommendedATA-2015Guidelinesrecommende甲状腺髓样癌的分子分型及治疗-课件SurgicalManagementofMTC●ATA-D(HST)-MEN2B
>1yr,TT+BiⅥLND;
●ATA-A~C(MOD~H)-MEN2A
basalCt<40pg/mL,TTwithoutBiⅥLNDisadequate.(Ct
<60ng/L,EliseiR,etal
;Ct
<70ng/L,QiXP,etal)SurgicalManagementofMTC●ATFemale,5.5yr;p.C634Y;bilateralMTC;DFS6yrFemale,5.5yr;p.C634Y;bilateResidualandRecurrentDisease
ResidualandRecurrent:approximately50%-80%,postoperationⅰCt<150pg/ml,residualdiseaseinthethyroidbedordraininglymphnodes;ⅱCt>150pg/ml,higherprobabilityofdistantmetastaticdisease;ⅲUS,CT/MRI;
ResidualandRecurrentDiseaseResidualandRecurrentDiseaseCytoreductive(Salvage)surgery
ⅰReducedCtlevelsinmanypatients;ⅱNormalizationoftheCtlevelsinuptoabout1/3ofpatients;ⅲTheriskofsurgicalcomplications↑
ResidualandRecurrentDiseaseMedicalManagementofAdvancedMetastaticDisease
①Cytotoxicchemotherapyinlimitedpatientswithrapidlyprogressivedisease
minimalbenefit
②RadionuclidetherapyI-131responsesonlyabout30%to35%,
③Somatostatinanalogsoctreotide
MedicalManagementofAdvancedMedicalManagementofAdvancedMetastaticDisease④TargetedtherapyMedicalManagementofAdvanced
Tyrosinekinasereceptorsanddownstreameffectors
TyrosinekinasereceptorsandMedicalManagementofAdvancedMetastaticDisease④Targetedtherapy
Tyrosinekinaseinhibitors(TKIs)--
RET,EGFR,VEGFR,andFGFR,MET
Twosmall-moleculeTKIs,vandetanib(Apr2011)andcabozantinib(Nov2012),arecurrentlyavailableasapprovedagentsforthetreatmentofadvancedorprogressiveMTCandprovidesignificantincreasesinprogression-freesurvival(PFS).
MedicalManagementofAdvancedMedicalManagementofAdvancedMetastaticDisease●Vandetanib--RET,EGFR,VEGFRandEGFRⅰtwophase2(hereditaryonly)
dosedaily300mg100mgPR20%16%stabledisease53%53%medianPFS27.9months>24weeksⅱphase3in331patients
(H-S-MTC)300mg/d;objectiveresponserate(ORR)45%;medianPFS30.5months.
QTprolongation(14%),diarrhea(56%),rash(45%),hypertension(32%),headache(26%)….MedicalManagementofAdvancedMedicalManagementofAdvancedMetastaticDisease●Cabozantinib--RET,VEGFRandc-MET
lesssuitableforelderlypatientsforwhomtheprevalenceofcardiovascularriskfactors
TheestimatedmedianPFSwithvandetanibisnumericallylongerthanwithcabozantinib
Choice:
Thepatient’scomorbidconditionsandthetoxicityprofilethatthepatientiswillingtobear
MedicalManagementofAdvancedMedicalManagementofAdvancedMetastaticDisease●othersmall-moleculekinaseinhibitorssunitinib,sorafenib,andpazopanib
●Othertargetedtreatments
mammaliantargetofrapamycin(mTOR)inhibitor-everolimus
MedicalManagementofAdvanced
Prevention-PD/PGDPreimplantationgeneticdiagnosisofmultipleendocrineneoplasiatype2Ausinginformativemarkersidentifiedbytargetedsequencing[J],Thyroid,2017.(UR)
Prevention-PD/PGDPreimplantatAcknowledgementAcknowledgement甲状腺髓样癌的分子分型及治疗-课件甲状腺髓样癌的分子分型及治疗
解放军第一一七医院
戚晓平甲状腺髓样癌的分子分型及治疗解放军第一一概况Histologicsubtypesof
thyroidcancer
①Papillary:approximately80%ofallthyroidmalignancies;
②FollicularandHürthle:approximately11%;
③Medullary:lessthan5%-8%;
④Anaplastic:lessthan2%.
概况HistologicsubtypesofthyroIntroductionMedullarythyroidcancer(MTC)①SporadicMTC:
approximately75%;>50%somatic
RET
mutations(p.M918T)-predictapoorprognosis
②HereditaryMTC:
approximately25%;
98%Germline
RET
mutations,MEN2A(~95%)andMEN2B(~5%)
Arisesfromtheneuralcrest-derived,calcitonin-secreting,parafollicularCcellsofthethyroidgland
IntroductionMedullarythyroidIntroduction①SporadicMTC:
asolitaryandunilateralorapalpablecervicallymphnode
②HereditaryMTC:multicentricandbilateraltheuppertomiddlepartsofthethyroidlobes
Introduction①SporadicMTC:aIntroductionInvolvementofcervicallymphnodesisanearlyandcommonmanifestationintheclinicalcourseofthedisease,with35%to50%ormore,another10%to15%mayhavedistantmetastasesatthetimeofinitialpresentation;
DistantmetastaticspreadofMTCfrequentlyinvolvesthemediastinalnodes,lung,liver(>90%),andbones.
IntroductionInvolvementofcep.C611YMEN2Ap.C611YMolecularAberrations
(overexpression)
①RET
mutations②VEGFR-2③MET④EGFR⑤
FGFR⑥
RAS
(sMTC---56%KRAS+;12%HRAS)(MutationsinRASappeartobemutuallyexclusiveofRETabnormalities)
SomaticRETmutationsMolecularAberrations(overexpMolecularpathways①PI3K/Akt/mTOR②MAPK③JNK④RAS/ERKPlaycriticalrolesinregulatingcellproliferation,differentiation,motility,apoptosis,andsurvival
Molecularpathways①PI3K/Akt/DiagnosisandMonitoring①FNA,USandCT,MRIorECT(Ct>500pg/mL);
②DNAanalysisfortheRETgermlinemutation
ATA-2015,ETA-2013,NCCN-2017Guidelinesrecommend
③
TheMTCspecimenispositivelystainedforCt,chromograninA,andCEAorCongoRed.
DiagnosisandMonitoring①FNA,DiagnosisandMonitoring
④Serum-basedbiomarkers:
calcitoninandCEA(>50%)Preoperative:ⅰCEA(↑),Ct(-)--poorlydifferentiatedtumors,Rare;
ⅱCt>100pg/mL--predictive–MTC;
ⅲCt>150pg/mL,CEA>30ng/L--regionalspread;
ⅳCt>3000pg/mL,CEA>100ng/L--distantspread.PredictorsofMTCprogress,includingrecurrenceandsurvival
DiagnosisandMonitoring④SeruDiagnosisandMonitoring④Serum-basedbiomarkers:
calcitoninandCEAPostoperative:ⅰCt(↑)--thefirstsignoftumorrecurrence;ⅱCt(-)andsCt(-)--10-yearsurvivalrates(SR)of100%;yearlyCtmeasurements;
ⅲCtdoublingtimes(DT)>1yr(2yr)--5-and10-yrSR
of98%and95%;CEADT>1yr--5-and10-yrSRof100%；
ⅳCtDT<1yr(6mon)--5-and10-yrSR
of36%and18%（25%and8%）;CEA<1year--5-and10-yrSRof43%and21%.
PredictorsofMTCprogress,includingrecurrenceandsurvival
DiagnosisandMonitoring④SerumDiagnosisandMonitoring●10-yrSRforpatientswithstagesI,II,III,andIVMTCare100%,93%,71%,and21%,respectively;●SRforpatientswithdistantmetastasesMTCis51%at1yr,26%at5yr,and10%at10yr,respectively.
●DiagnosisandMonitoring●10-yrATA-2015GuidelinesrecommendedATA-2015Guidelinesrecommende甲状腺髓样癌的分子分型及治疗-课件MEN2B-denovo
RET
p.M918TMEN2B-denovoRETp.M918TMEN2B-denovo
RET
p.M918TMEN2B-denovoRETp.M918TMEN2A-CLA,RETp.C634R/FMEN2A-CLA,RETp.C634R/F甲状腺髓样癌的分子分型及治疗-课件SurgicalManagementofMTC
①Theminimumextentofsurgeryisatotalthyroidectomy(TT)withbilateralcentralneckdissection(BiⅥ)
(TT+BiⅥLND);②TTwithipsilaterallateralcompartmentneckdissection;
(Unilaterallateral
LN+,MTCsize>1cm)
(TT+BiⅥ+UniLND)③TTwithbilaterallateralcompartmentneckdissection.(BilateraltumorsorextensiveLN+onthecontralateralside)
(TT+BiⅥ+BiLND)SurgicalManagementofMTC①Th甲状腺髓样癌的分子分型及治疗-课件SurgicalManagementofMTC***CurrentrecommendationsforthetimingofprophylacticthyroidectomydependsontheriskleveloftheRETmutationinhereditaryMTC(MEN2).
SurgicalManagementofMTCATA-2015GuidelinesrecommendedATA-2015Guidelinesrecommende甲状腺髓样癌的分子分型及治疗-课件SurgicalManagementofMTC●ATA-D(HST)-MEN2B
>1yr,TT+BiⅥLND;
●ATA-A~C(MOD~H)-MEN2A
basalCt<40pg/mL,TTwithoutBiⅥLNDisadequate.(Ct
<60ng/L,EliseiR,etal
;Ct
<70ng/L,QiXP,etal)SurgicalManagementofMTC●ATFemale,5.5yr;p.C634Y;bilateralMTC;DFS6yrFemale,5.5yr;p.C634Y;bilateResidualandRecurrentDisease
ResidualandRecurrent:approximately50%-80%,postoperationⅰCt<150pg/ml,residualdiseaseinthethyroidbedordraininglymphnodes;ⅱCt>150pg/ml,higherprobabilityofdistantmetastaticdisease;ⅲUS,CT/MRI;
ResidualandRecurrentDiseaseResidualandRecurrentDiseaseCytoreductive(Salvage)surgery
ⅰReducedCtlevelsinmanypatients;ⅱNormalizationoftheCtlevelsinuptoabout1/3ofpatients;ⅲTheriskofsurgicalcomplications↑
ResidualandRecurrentDiseaseMedicalManagementofAdvancedMetastaticDisease
①Cytotoxicchemotherapyinlimitedpatientswithrapidlyprogressivedisease
minimalbenefit
②RadionuclidetherapyI-131responsesonlyabout30%to35%,
③Somatostatinanalogsoctreotide
MedicalManagementofAdvancedMedicalManagementofAdvancedMetastaticDisease④TargetedtherapyMedicalManagementofAdvanced
Tyrosinekinasereceptorsanddownstreameffectors
TyrosinekinasereceptorsandMedicalManagementofAdvancedMetastaticDisease④Targetedtherapy
Tyrosinekinaseinhibitors(TKIs)--
RET,EGFR,VEGFR,andFGFR,MET
Twosmall-moleculeTKIs,vandetanib(Apr2011)andcabozantinib(Nov2012),arecurrentlyavailableasapprovedagentsforthet
温馨提示
- 1. 本站所有资源如无特殊说明，都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等，如果需要附件，请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸，网页内容里面会有图纸预览，若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间，仅对用户上传内容的表现方式做保护处理，对用户上传分享的文档内容本身不做任何修改或编辑，并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容，请与我们联系，我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024年度电机产品质量监控与提升合同2篇
- 2024年度广告设计分包服务合同5篇
- 2024年度保险合同：某保险公司与某企业就为企业员工提供保险服务达成协议2篇
- 2024年度碎石供应商鹅卵石运输合同
- 2024年度电梯安装工程质量监督合同2篇
- 2024年度软件开发与购买合同详细条款
- 2024年度航空器材仓储租赁合同
- 2024年度汽车租赁挂靠经营协议3篇
- 2024年度租赁协议：某公司租赁商务楼办公空间
- 二零二四年度产业园区物业管理与服务合同
- 5.5 跨学科实践：制作望远镜到西安 八年级物理上册人教版2024
- 《ST欧浦大股东掏空行为案例研究》
- 医院改扩建工程可行性研究报告（论证后）
- 【初中生物】第三章微生物检测试题 2024-2025学年人教版生物七年级上册
- 六年级数学上册 （基础版）第4章《比》单元培优拔高测评试题（学生版）（人教版）
- 《中华人民共和国药品管理法》
- 医科大学2024年12月肿瘤护理学作业考核试题答卷
- 2024水样采集与保存方法
- 2025届高考语文一轮复习：二元思辨类作文思辨关系高阶思维
- 糖尿病患者体重管理专家共识（2024年版）解读
- 《中国慢性阻塞性肺疾病基层诊疗与管理指南（2024年）》解读
评论
0/150
提交评论